N-methyl-3,4-dihydroisoquinolin-2(1H)-amine | 90872-67-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-methyl-3,4-dihydroisoquinolin-2(1H)-amine
• 英文别名: (3,4-dihydro-1H-isoquinolin-2-yl)-methyl-amine；2--amino-1.2.3.4-tetrahydroisochinolin；N-methyl-3,4-dihydro-1H-isoquinolin-2-amine
• CAS: 90872-67-6
• 化学式: C₁₀H₁₄N₂
• 分子量: 162.235
• InChiKey: FKSNFGGLYGSUSO-UHFFFAOYSA-N

物化性质

• 沸点：
  85-88 °C(Press: 0.85 Torr)
• 密度：
  1.07±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-methyl-3,4-dihydroisoquinolin-2(1H)-amine 、 4-氯苯基氯甲酸酯 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 (3,4-Dihydro-1H-isoquinolin-2-yl)-methyl-carbamic Acid 4-chloro-phenyl Ester
  参考文献：
  名称：

  Carbazates as potent inhibitors of hormone-sensitive lipase

  摘要：

  The central role of adipose tissue hormone-sensitive lipase in regulating fatty acid metabolism makes it a potential pharmacological target for the prevention of peripheral insulin resistance in obese, prediabetic and diabetic individuals. The synthesis of a new series of carbazates is presented. Modification of the phenolic 4-position in a series of 1,2,3,4-tetrahydroisoquinoline and morpholine derived carbazates, yielded inhibitors of the catalytic activity of this enzyme with nanomolar potency. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.01.038
• 作为产物：
  描述：

  1,2,3,4-四氢异喹啉-2-胺 在 lithium aluminium tetrahydride 、 溶剂黄146 作用下， 以 四氢呋喃 、 乙醚 、 水 为溶剂， 反应 0.84h， 生成 N-methyl-3,4-dihydroisoquinolin-2(1H)-amine
  参考文献：
  名称：

  Discovery and structural analyses of S-adenosyl-l-homocysteine hydrolase inhibitors based on non-adenosine analogs

  摘要：

  Optimization of a new series of S-adenosyl-L-homocysteine hydrolase (AdoHcyase) inhibitors based on non-adenosine analogs led to very potent compounds 14n, 18a, and 18b with IC50 values of 13 +/- 3, 5.0 +/- 2.0, and 8.5 +/- 3.1 nM, respectively. An X-ray crystal structure of AdoHcyase with NAD(+) and 18a showed a novel open form co-crystal structure. 18a in the co-crystals formed intramolecular eight membered ring hydrogen bond formations. A single crystal X-ray structure of 14n also showed an intramolecular eight-membered ring hydrogen bond interaction. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.05.018

文献信息

• THERAPEUTIC AGENT FOR CEREBRAL INFARCTION
  申请人：Nakao Akira

  公开号：US20120196824A1

  公开（公告）日：2012-08-02

  The invention provides a therapeutic drug for ischemic stroke. The therapeutic drug has the formula (I) wherein each symbol is as defined herein, or a pharmacologically acceptable salt thereof, or a solvate thereof, as an active ingredient.

  这项发明提供了一种用于缺血性中风的治疗药物。该治疗药物具有如下式（I）的化学式，其中每个符号如本文所定义，或其药理学上可接受的盐，或其溶剂化物，作为活性成分。
• [EN] INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE<br/>[FR] INHIBITEURS DE L'INDOLÉAMINE 2,3-DIOXYGÉNASE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2020023355A1

  公开（公告）日：2020-01-30

  The present invention provides compounds of formula (I): wherein all of the variables are as defined herein. These compounds are inhibitors of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmune diseases.

  本发明提供了以下化合物（I）的公式：其中所有变量如本文所定义。这些化合物是色氨酸2,3-二氧化酶（IDO）的抑制剂，可用作治疗增殖性疾病，如癌症、病毒感染和/或自身免疫疾病的药物。
• Homocysteine synthase inhibitor
  申请人：Nakao Akira

  公开号：US08513235B2

  公开（公告）日：2013-08-20

  The invention provides a homocysteine synthase inhibitor useful for the prophylaxis or treatment of diseases involving homocysteine synthase. The homocysteine synthase inhibitor is a compound of the formula (I) wherein each symbol is as defined herein, or a pharmacologically acceptable salt thereof, or a solvate thereof.

  本发明提供了一种对于预防或治疗涉及到同型半胱氨酸合酶的疾病有用的同型半胱氨酸合酶抑制剂。该同型半胱氨酸合酶抑制剂是式(I)的化合物，其中每个符号如本文所定义，或其药理学可接受的盐，或其溶剂化物。
• HOMOCYSTEINE SYNTHASE INHIBITOR
  申请人：Nakao Akira

  公开号：US20110034440A1

  公开（公告）日：2011-02-10

  The invention provides a homocysteine synthase inhibitor useful for the prophylaxis or treatment of diseases involving homocysteine synthase. The homocysteine synthase inhibitor is a compound of the formula (I) wherein each symbol is as defined herein, or a pharmacologically acceptable salt thereof, or a solvate thereof.

  本发明提供了一种同型半胱氨酸合酶抑制剂，可用于预防或治疗涉及同型半胱氨酸合酶的疾病。该同型半胱氨酸合酶抑制剂是公式(I)的化合物，其中每个符号如本文所定义，或其药理学上可接受的盐，或其溶剂化物。
• COMPOUND INHIBITING BUTYRYLCHOLINESTERASE
  申请人：Julius-Maximilians-Universität Würzburg

  公开号：EP3683219A1

  公开（公告）日：2020-07-22

  The invention concerns a compound according to formula wherein 3 < n < 11, wherein R comprises or consists of a heterocycle comprising one tertiary amino group providing the binding of R to the rest of the molecule and at least three carbon atoms, wherein all carbon atoms of the heterocycle are unsubstituted.

  本发明涉及一种根据式 其中 3 < n < 11，R 包括或由杂环组成，杂环由一个提供 R 与分子其余部分结合的叔氨基和至少三个碳原子组成，其中杂环的所有碳原子均未被取代。